Keywords: CAE, cutaneous adverse events; GIST, gastrointestinal stromal tumor; KIT, tyrosine-protein kinase KIT/CD117; LCV; LCV, leukocytoclastic vasculitis; PDGFRA, platelet-derived growth factor receptor alpha; TK, tyrosine kinase; TKI, tyrosine kinase inhibitor; avapritinib; cutaneous adverse event; imatinib; leukocytoclastic vasculitis; oncology; prednisone taper; purpura; rash; receptor tyrosine kinase; targeted therapy.